Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study of SHR-1210 (PD-1 Antibody) in Combination With Apatinib or Chemotherapy (FOLFOX4 or GEMOX) in Subjects With Advanced Primary Liver CancerPLCor Biliary Tract Carcinoma (BTC)

Next Previous
Trial Profile

A Phase 2 Study of SHR-1210 (PD-1 Antibody) in Combination With Apatinib or Chemotherapy (FOLFOX4 or GEMOX) in Subjects With Advanced Primary Liver CancerPLCor Biliary Tract Carcinoma (BTC)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Camrelizumab (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Oxaliplatin; Rivoceranib
  • Indications Biliary cancer; Gallbladder cancer; Liver cancer
  • Focus Adverse reactions
  • Sponsors Jiangsu Hengrui Medicine Co.

Most Recent Events

  • 05 Feb 2026 Last checked against ClinicalTrials.gov record.
  • 26 Apr 2022 Planned End Date changed from 1 Mar 2019 to 1 Apr 2022.
  • 26 Apr 2022 Planned primary completion date changed from 1 Nov 2018 to 1 Apr 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top